title: Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo.
abstract: THREE DOCETAXEL (DX) LIPID CONJUGATES: 2'-lauroyl-docetaxel (C12-DX), 2'-stearoyl-docetaxel (C18-DX), and 2'-behenoyl-docetaxel (C22-DX) were synthesized to enhance drug loading, entrapment, and retention in liquid oil-filled lipid nanoparticles (NPs). The three conjugates showed ten-fold higher solubility in the liquid oil phase Miglyol 808 than DX. To further increase the drug entrapment efficiency in NPs, orthogonal design was performed. The optimized formulation was composed of Miglyol 808, Brij 78, and Vitamin E tocopheryl polyethylene glycol succinate (TPGS). The conjugates were successfully entrapped in the reduced-surfactant NPs with entrapment efficiencies of about 50%-60% as measured by gel permeation chromatography (GPC) at a final concentration of 0.5 mg/mL. All three conjugates showed 45% initial burst release in 100% mouse plasma. Whereas C12-DX showed another 40% release over the next 8 hours, C18-DX and C22-DX in NPs showed no additional release after the initial burst of drug. All conjugates showed significantly lower cytotoxicity than DX in human DU-145 prostate cancer cells. The half maximal inhibitory concentration values (IC(50)) of free conjugates and conjugate NPs were comparable except for C22-DX, which was nontoxic in the tested concentration range and showed only vehicle toxicity when entrapped in NPs. In vivo, the total area under the curve (AUC(0-∞)) values of all DX conjugate NPs were significantly greater than that of Taxotere, demonstrating prolonged retention of drug in the blood. The AUC(0-∞) value of DX in Taxotere was 8.3-fold, 358.0-fold, and 454.5-fold lower than that of NP-formulated C12-DX, C18-DX, and C22-DX, respectively. The results of these studies strongly support the idea that the physical/chemical properties of DX conjugates may be fine-tuned to influence the affinity and retention of DX in oil-filled lipid NPs, which leads to very different pharmacokinetic profiles and blood exposure of an otherwise potent chemo-therapeutic agent. These studies and methodologies may allow for improved and more potent nanoparticle-based formulations.
authors.affiliation: Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
authors.forename: Lan
authors.initials: L
authors.lastname: Feng
authors.forename: Huali
authors.initials: H
authors.lastname: Wu
authors.forename: Ping
authors.initials: P
authors.lastname: Ma
authors.forename: Russell J
authors.initials: RJ
authors.lastname: Mumper
authors.forename: S Rahima
authors.initials: SR
authors.lastname: Benhabbour
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D019540:Area Under Curve; D045744:Cell Line, Tumor; D002470:Cell Survival; D003692:Delayed-Action Preparations; D000077143:Docetaxel; D004337:Drug Carriers / Q000737:chemistry*; D005227:Fatty Acids / Q000737:chemistry*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry; D012995:Solubility; D043823:Taxoids / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics*; D014280:Triglycerides / Q000737:chemistry; D014810:Vitamin E / Q000031:analogs & derivatives / Q000737:chemistry
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005227:Fatty Acids; D043823:Taxoids; D014280:Triglycerides; D014810:Vitamin E; D000077143:Docetaxel; D011092:Polyethylene Glycols; C014225:tocophersolan
references.citation: Pharm Res. 2006 Apr;23(4):752-8
references.pmid: 16550475
references.citation: J Clin Oncol. 1995 Oct;13(10):2643-55
references.pmid: 7595719
references.citation: J Med Chem. 2008 Jun 12;51(11):3288-96
references.pmid: 18465845
references.citation: Cancer Res. 1993 Feb 1;53(3):523-7
references.pmid: 8093854
references.citation: Science. 2004 Mar 19;303(5665):1818-22
references.pmid: 15031496
references.citation: Anticancer Drugs. 2001 Feb;12(2):117-28
references.pmid: 11261884
references.citation: J Natl Cancer Inst. 1992 Dec 2;84(23):1781-8
references.pmid: 1359154
references.citation: Biomaterials. 2009 Oct;30(29):5751-6
references.pmid: 19656559
references.citation: J Control Release. 2001 Jul 6;74(1-3):233-6
references.pmid: 11489499
references.citation: Biomacromolecules. 2007 Jul;8(7):2250-7
references.pmid: 17579476
references.citation: J Med Chem. 1989 Apr;32(4):788-92
references.pmid: 2564894
references.citation: Methods Enzymol. 2005;391:97-117
references.pmid: 15721376
references.citation: Org Biomol Chem. 2009 Sep 7;7(17):3437-46
references.pmid: 19675898
references.citation: J Liposome Res. 2011 Sep;21(3):237-44
references.pmid: 21158702
references.citation: Biomaterials. 2011 Mar;32(8):2183-93
references.pmid: 21176955
references.citation: J Clin Oncol. 1993 May;11(5):950-8
references.pmid: 8098059
references.citation: Biomaterials. 2009 Jan;30(2):226-32
references.pmid: 18851881
references.citation: J Control Release. 2003 Sep 4;91(3):417-29
references.pmid: 12932719
references.citation: Int J Nanomedicine. 2006;1(3):297-315
references.pmid: 17717971
references.citation: J Clin Oncol. 1994 Jul;12(7):1458-67
references.pmid: 7912725
references.citation: Anticancer Drugs. 1995 Jun;6(3):356-68
references.pmid: 7670133
references.citation: Cancer Res. 2000 Mar 1;60(5):1417-25
references.pmid: 10728708
references.citation: Eur J Pharm Biopharm. 2009 May;72(1):9-17
references.pmid: 19111929
references.citation: Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):110S-125S
references.pmid: 9322878
references.citation: Int J Pharm. 2009 Sep 8;379(1):174-80
references.pmid: 19524029
references.citation: Cancer Res. 1993 Mar 1;53(5):1037-42
references.pmid: 8094996
references.citation: Cancer Res. 2009 May 1;69(9):3918-26
references.pmid: 19383919
references.citation: J Natl Cancer Inst. 1991 Feb 20;83(4):288-91
references.pmid: 1671606